1. Home
  2. TDAC vs AARD Comparison

TDAC vs AARD Comparison

Compare TDAC & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TDAC
  • AARD
  • Stock Information
  • Founded
  • TDAC 2022
  • AARD 2017
  • Country
  • TDAC United States
  • AARD United States
  • Employees
  • TDAC N/A
  • AARD N/A
  • Industry
  • TDAC
  • AARD Biotechnology: Pharmaceutical Preparations
  • Sector
  • TDAC
  • AARD Health Care
  • Exchange
  • TDAC NYSE
  • AARD Nasdaq
  • Market Cap
  • TDAC 220.4M
  • AARD 216.6M
  • IPO Year
  • TDAC 2024
  • AARD 2025
  • Fundamental
  • Price
  • TDAC $10.08
  • AARD $6.98
  • Analyst Decision
  • TDAC
  • AARD Strong Buy
  • Analyst Count
  • TDAC 0
  • AARD 4
  • Target Price
  • TDAC N/A
  • AARD $31.50
  • AVG Volume (30 Days)
  • TDAC 115.3K
  • AARD 115.0K
  • Earning Date
  • TDAC 01-01-0001
  • AARD 01-01-0001
  • Dividend Yield
  • TDAC N/A
  • AARD N/A
  • EPS Growth
  • TDAC N/A
  • AARD N/A
  • EPS
  • TDAC N/A
  • AARD N/A
  • Revenue
  • TDAC N/A
  • AARD N/A
  • Revenue This Year
  • TDAC N/A
  • AARD N/A
  • Revenue Next Year
  • TDAC N/A
  • AARD N/A
  • P/E Ratio
  • TDAC N/A
  • AARD N/A
  • Revenue Growth
  • TDAC N/A
  • AARD N/A
  • 52 Week Low
  • TDAC $10.00
  • AARD $7.74
  • 52 Week High
  • TDAC $10.20
  • AARD $19.58
  • Technical
  • Relative Strength Index (RSI)
  • TDAC N/A
  • AARD N/A
  • Support Level
  • TDAC N/A
  • AARD N/A
  • Resistance Level
  • TDAC N/A
  • AARD N/A
  • Average True Range (ATR)
  • TDAC 0.00
  • AARD 0.00
  • MACD
  • TDAC 0.00
  • AARD 0.00
  • Stochastic Oscillator
  • TDAC 0.00
  • AARD 0.00

About TDAC TRANSLATIONAL DEVELOPMENT ACQUISITI

Translational Development Acquisition Corp is a newly organized blank check company.

About AARD Aardvark Therapeutics Inc. Common Stock

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Share on Social Networks: